← Markets

Absci Corporation

ABSI · NASDAQ

Market closed$8.30$0.065000 (+0.79%)After hours $8.30 · +0.06%

Key statistics

Previous close$8.23
Open$7.96
Day high$8.54
Day low$7.58
52-week high$12.06
52-week low$2.24
Market cap1.41B
Volume3.71M
Average volume6.09M
P/E ratio-9.65
Forward P/E—
EPS-0.86
Dividend yield0.00%

Market context

Why it moved

Absci (ABSI) edged modestly higher amid positive sentiment in the AI drug discovery space, boosted by visibility from the upcoming Jones AI Day panel featuring Absci alongside other leading AI companies.

NatlawreviewAistockwireInstagramSynbiointelDailybeirut

What is happening

Recent company-specific developments and publisher coverage.

July 18, 2026Absci Corporation edged higher, consolidating after a transformative June 24 catalyst when shares surged 36% on positive Phase 1 data for ABS-201 — its AI-designed hair loss and endometriosis drug — paired with a $100M Eli Lilly-backed equity raise. With Q2 earnings scheduled for August 11 and proof-of-concept data from the ongoing HEADLINE study expected in H2 2026, investors are watching the clinical readout closely. Thursday's modest gain came against a broader risk-off backdrop, as chip stocks and Nasdaq sold off on AI spending concerns and escalating U.S.-Iran tensions.

0.7898

July 17, 2026Absci Corporation tumbled nearly 16% — its sharpest single-day decline in recent memory — on above-average volume, likely driven by broader selling pressure in AI-driven biotech and growth names amid a tech-led market pullback on July 16. While no company-specific catalyst has emerged, investor anxiety ahead of Absci's Q2 2026 earnings report scheduled for August 11 may be amplifying the move, as the clinical-stage generative AI drug discovery company carries high valuation risk with no approved products. The broader healthcare ETF (XLV) closed modestly lower, suggesting the selloff is idiosyncratic to Absci rather than sector-wide.

-15.6762

July 16, 2026Absci fell nearly 5% amid continued investor digestion of mixed signals: a Wall Street Zen sell downgrade issued July 12 cited weak Q1 revenue of just $0.21M versus $1.39M expected, weighing on sentiment despite a broader analyst consensus of 'Moderate Buy' with an average price target of $13.43. The company also announced its Q2 2026 earnings date for August 11, keeping investors focused on upcoming proof-of-concept data for ABS-201, its AI-designed hair loss and endometriosis drug, which had triggered a 36% surge in late June following positive clinical data and a $100M Eli Lilly-backed offering.

-4.5943

July 15, 2026Absci Corporation closed essentially flat, holding near the $10.20 level, as the company announced it will report Q2 2026 results on August 11 — a near-term catalyst investors will be watching closely for clinical updates on its ABS-201 hair loss and endometriosis drug. The stock has pulled back from highs above $10.60 following a Wall Street Zen downgrade to sell on July 12, though the broader analyst consensus remains a Moderate Buy with a $13.43 average price target, supported by recent upgrades from Truist (raised to $17), HC Wainwright (raised to $16), and BTIG (raised to $13). The macro backdrop offered modest support, with a cooler-than-expected June CPI report lifting broader markets, while healthcare sector ETF XLV faced headwinds from weakness in Abbott and UnitedHealth.

0.1959

July 14, 2026Absci shares declined amid a broader market selloff driven by renewed U.S.-Iran hostilities, surging oil prices, and a chip stock selloff rattling risk sentiment — headwinds that weighed on small-cap biotech names. Adding to the pressure, Wall Street Zen downgraded Absci to Sell on Sunday, though the broader analyst consensus remains a Moderate Buy with an average target of $13.43. The stock remains up sharply on the year following its late June surge on positive ABS-201 hair loss trial data and a $100M Eli Lilly-backed equity raise.

-3.6792

July 11, 2026Absci Corporation tumbled sharply, giving back a portion of its extraordinary year-to-date gains of over 225%, as rising put/call ratios and ARK Invest selling activity signaled growing caution among institutional investors. The pullback follows a June 24 surge of 36%—its best single day ever—driven by positive Phase 1 data for ABS-201 (its AI-designed hair loss and endometriosis drug) and a $100M Eli Lilly-backed capital raise; the broader healthcare sector (XLV) also faced modest pressure, while geopolitical tensions from Iran-U.S. military escalations added macro headwinds earlier in the week.

-7.585

July 10, 2026Absci Corporation gained, closing near recent highs as investor sentiment remained supported by a confluence of positive catalysts. Director Mary Szela's open-market purchase of 12,900 shares at $11.54 on June 30 reinforced insider confidence, while analyst price targets from H.C. Wainwright ($16 Buy) and Guggenheim ($15) reflect optimism around lead asset ABS-201 following favorable Phase 1/2a HEADLINE safety data and a $100M equity raise that extended the runway. Biotech broadly emerged as the market's hottest sector, with Jim Cramer highlighting M&A tailwinds under the new FDA leadership — a favorable backdrop for clinical-stage AI drug discovery names like Absci.

3.3333

July 9, 2026Absci Corporation shares fell amid a broader market risk-off session triggered by President Trump declaring the U.S.-Iran ceasefire 'over,' sending oil prices surging 5%+ and dragging major indices lower. Despite the macro headwinds, ABSI remains a focus for biotech investors after reporting encouraging interim Phase 1 data for ABS-201, its anti-prolactin receptor antibody targeting androgenetic alopecia, and advancing the HEADLINE trial into multiple ascending dose stages — catalysts that have driven a ~222% year-to-date gain. Jim Cramer's recent call labeling biotech 'the hottest group in the market' and predicting an M&A wave under new FDA leadership adds to bullish sector sentiment, even as geopolitical volatility weighs on near-term price action.

-2.03

Zacks Investment Research · July 18, 2026Wall Street Analysts Predict a 28.3% Upside in ABSCI CORP (ABSI): Here's What You Should KnowGlobeNewswire · July 14, 2026Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026Moomoo · June 29, 2026Absci Stock (ABSI) Opinions on Positive Phase 1 Data for ABS-201Clinical Trials Arena · June 26, 2026Lilly-backed Absci banks $100m to progress endometriosis, hair loss therapySeeking Alpha · June 24, 2026Absci: Eli Lilly Backs Alopecia Data With Funding, But Risks Remain (NASDAQ:ABSI)The Business Journals · June 24, 2026Portland-area biotech receives $100M investment led by Eli LillyStock Titan · June 24, 2026Absci raises $100M as Lilly joins investors backing AI drug programStocktwits · June 24, 2026ABSI Stock Eyes Best Day Ever After Positive Hair Loss Drug Data, $100M Lilly-Backed Raise
Benzinga · July 2, 2026Truist Securities Maintains Buy on Absci, Raises Price Target to $17
Benzinga · July 1, 2026Anthropic Is Going All In on Drug Discovery Just as Pharma Stops Talking About AI
Benzinga · June 24, 2026Needham Reiterates Buy on Absci, Raises Price Target to $11
Mt Newswire · June 24, 2026Absci's ABS-201 Phase 1 Data De-Risks Hair Loss Program Ahead of Efficacy Readout, Truist Says
Benzinga · June 24, 2026Absci Raises $100 Million In Equity To Fund AI-Designed Hair Loss And Endometriosis Program
Mt Newswire · June 24, 2026Absci Prices $100 Million Share Offering
Mt Newswire · June 24, 2026Absci Says Phase 1 Data Support Extended Dosing for ABS-201 Hair Loss Therapy
Benzinga · June 24, 2026Absci Prices $100M Underwritten Offering Of 13,495,277 Shares At $7.41 Per Share

Peers

S&P 500SPX · $7,457.69-1.01%Recursion Pharmaceuticals, Inc.RXRX · $2.95-2.48%Relay Therapeutics, Inc.RLAY · $19.91+2.79%Intellia Therapeutics, Inc.NTLA · $11.38-4.09%AbCellera Biologics Inc.ABCL · $6.47+4.95%Arcturus Therapeutics Holdings Inc.ARCT · $6.05-2.10%Monte Rosa Therapeutics, Inc.GLUE · $24.56+6.04%Rigel Pharmaceuticals, Inc.RIGL · $40.54-2.71%Cartesian Therapeutics, Inc.RNAC · $8.26-0.84%Candel Therapeutics, Inc.CADL · $10.18+7.38%Nektar TherapeuticsNKTR · $68.26+1.80%Tempus AI, Inc.TEM · $52.47-2.09%